Xanthine Oxidase Inhibitor
Pregnancy: C
Allopurinol
Brand names: Zyloprim, Zyloric
Adult dose
Dose: 100–300mg once daily
Route: Oral
Frequency: Once daily
Start low (100mg/day) and titrate up. Reduce dose in renal impairment: eGFR 10–50: max 100mg/day; eGFR <10: 100mg every 2–3 days.
Clinical pearls
- Start at 100mg/day AFTER acute gout attack resolves — never start during flare
- HLA-B*58:01 allele increases risk of severe cutaneous reactions — screen in Han Chinese, Thai, Korean populations before starting
- Flare prophylaxis with colchicine 500mcg BD for first 3–6 months of treatment
- Target urate <360 µmol/L (or <300 µmol/L with tophi)
- Febuxostat is alternative if intolerant, but higher cardiovascular risk
Contraindications
- Acute gout attack (do not initiate during acute attack)
- Azathioprine or 6-MP use without dose reduction
Side effects
- Rash (can progress to SJS/TEN)
- Hypersensitivity syndrome (DRESS)
- Nausea
- Hepatitis
- Renal failure
Interactions
- Azathioprine/6-mercaptopurine — allopurinol inhibits their metabolism → toxicity (reduce AZA dose by 75%)
- Warfarin — increases anticoagulant effect
- Ampicillin — increased rash risk
Monitoring
- Serum uric acid (4–6 weeks after dose change)
- Renal function
- LFTs
- FBC
Reference: BSR Guidelines for Gout 2017; ACR Gout Guidelines 2020. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- Tumor Lysis Syndrome Risk (Cairo-Bishop) · Oncological Emergency
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
Pathways
- Acute Pyelonephritis · NICE; BAUS; RCOG — CG109, NG109
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024